To further assess disease burden, investigators contacted approximately 600 households during October 17-21 by calling randomly selected listed telephone numbers. One adult in each household was asked whether any members of the household had developed conjunctivitis (defined as the onset of redness, tearing, swelling, itching, and/or burning around one or both eyes of at least 1 day's duration) within the preceding 8 weeks. Approximately 10% of households reported at least one case of conjunctivitis, and cases were distributed widely across the island. The selfreported average duration of symptoms was 5 days.
Preliminary results from testing of laboratory specimens from St. Croix indicate that the probable agent is coxsackievirus A24 variant (CA24v).
Control measures included disseminating public health information by press release and radio interviews and distribution of fact sheets by physicians' offices, public health clinics, and schools. St. Croix health authorities recommended that residents avoid social contact with persons who have AHC, including indirect contact (e.g., sharing towels or beds), restrict persons with AHC from attending school and work while symptomatic, and increase handwashing. Editorial Note: Preliminary results from this ongoing investigation document that an outbreak of AHC occurred in St. Croix during September-October 1998. The role, if any, of Hurricane Georges in the outbreak is under investigation.
Outbreaks of AHC are characterized by high communicability, a short incubation period (1-2 days), and high secondary attack rates within households (1 ) . Some outbreaks have been associated with rapid and efficient transmission, affecting ≥50% of persons in communities within a 1-2-month period. Spread of the virus appears to be related to crowding and poor hygiene and is thought to occur primarily by personto-person contact or contact with fomites (e.g., contaminated towels). Recovery is most often complete within 7 days, and complications, such as neurologic syndromes, related to the virus are extremely rare. Efforts to prevent AHC are particularly important because no effective treatment exists.
Epidemics of AHC began in 1969 in Africa and are primarily caused by enterovirus 70 (EV70) and CA24v. These viruses have caused pandemics of AHC in tropical coastal regions throughout the world (1 ) . Outbreaks of AHC have occurred periodically in the Caribbean beginning with EV70 in 1981 and CA24v in 1986 (2) (3) (4) (5) . During 1997, cases of AHC caused by CA24v were reported from several countries in Latin America (CDC, unpublished data, 1997). During September 12-October 17, AHC has been reported from several locations throughout the Caribbean region, including Antigua/Barbuda, Bahamas, British Virgin Islands, St. Christopher/Nevis, and Trinidad and Tobago (Caribbean Epidemiology Center, personal communication, 1998). CA24v has been identified from clinical isolates received from Suriname. Other countries in the Caribbean region could be affected during the current outbreak of CA24v-associated AHC.
Prevalence of Diagnosed Diabetes Among American Indians/Alaskan Natives -United States, 1996
Diabetes -Continued Since the early 1960s, diabetes has disproportionately affected American Indians/ Alaskan Natives (AIs/ANs) compared with other populations (1, 2 ) . Diabetes is a major cause of morbidity (such as blindness, kidney failure, lower-extremity amputation, and cardiovascular disease) and premature mortality in this population (3 ) . To update information about the prevalence of diabetes among AIs/ANs, data were analyzed from the Indian Health Service (IHS) national outpatient database for 1996 and were compared with the prevalence of diabetes among non-Hispanic whites in the United States. This report presents the findings of this analysis, which indicate that the prevalence of diabetes among AIs/ANs remains high and is approximately three times the prevalence among non-Hispanic whites.
Outpatient data were reported from 141 of the 166 service units in four geographic groups of tribes*; 25 service units (representing 11% of the population served by IHS) were excluded because the reported data were incomplete. The International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes 250.0-250.9 were used to identify persons with diabetes. The outpatient database includes unduplicated case reports of persons who attended the service unit one or more times during 1996 and for whom there was a diagnostic code of diabetes. The number of persons residing within the IHS service units were estimated from the U.S. census and birth and death rates. Approximately 60% of the estimated 2.3 million AIs/ANs residing in the United States are eligible to receive IHS services and use IHS medical facilities (4 ) . The prevalence of diabetes in the United States was estimated from the 1995 National Health Interview Survey (NHIS) (5 ) . Prevalence estimates were adjusted for age by the direct method using the 1980 U.S. population as the standard.
In 1996, an estimated 63,400 AIs/ANs who receive care from IHS had diabetes; 98.3% were aged ≥20 years. Of those aged ≥20 years, 49.7% were aged 45-64 years; 59.0% were women. The prevalence of diabetes increased with age-from 3.5% for persons aged 20-44 years to 21.5% for persons aged ≥65 years. The overall crude prevalence for those aged ≥20 years was 9.0% (Table 1) . The prevalence was greater among women (10.1%) than men (7.7%). The age-specific prevalence among AI/AN women was higher than among men, but the age-specific prevalence among nonHispanic white men was higher than among women.
Among AIs/ANs aged 20-44 years and 45-64 years, the prevalence of diabetes was more than three times that among non-Hispanic whites in the NHIS (3.5% versus 0.9%
[95% confidence interval (CI)=0.6%-1.2%] for persons aged 20-44 years and 19.0% versus 5.2% [95% CI=4.2%-6.2%] for persons aged 45-64 years). Among persons aged ≥65 years, the prevalence among AIs/ANs (21.5%) was approximately twice that among non-Hispanic whites (11.4% [95% CI=9.7%-13.1%]). The age-adjusted prevalence among persons aged ≥20 years was 2.8 times that among non-Hispanic whites in the same age group (10.9% versus 3.9% [95% CI=3.5%-4.3%]).
The prevalence of diabetes varied by tribal group-12.7% among the Plains tribes, 10.5% among the Southwestern tribes, 9.3% among the Woodland tribes, and 4.5% among the Pacific Coastal tribes. The age-adjusted prevalence of diabetes ranged from 1.5 to 4.1 times the prevalence among non-Hispanic whites. Among the tribes of the Plains and the Southwest, the age-adjusted prevalence of diabetes (15.9% and 13.5%, respectively) was greater than that for the total IHS population and was more than three times that among non-Hispanic whites. Editorial Note: Diabetes is a serious disease associated with severe morbidity and premature death that affects approximately 9% of AI/AN adults. In persons with type 1 or type 2 diabetes, aggressive glycemic control may prevent or delay diabetesrelated complications such as retinopathy, nephropathy, or neuropathy (6,7 ). Interventions that promote healthy behaviors may prevent or delay the onset of diabetes in persons at risk for developing type 2 diabetes (also known as noninsulin-dependent or adult-onset diabetes) (8 ) . As with other chronic disease prevention interventions, diabetes prevention efforts need to be ongoing and long-term before the impact on morbidity and mortality can be measured.
The findings in this analysis have at least four limitations. First, estimates of the AI/AN population are inaccurate because U.S. census estimates do not account for migration between service units and previously have underreported the number of AIs/ANs. Second, these data account only for those persons who are eligible to receive IHS services and use IHS medical facilities. The higher age-specific prevalence of diabetes among AI/AN women may be due to women seeking health care more frequently than men (4 ) . Moreover, the data represent diagnosed cases of diabetes being treated and underestimate the true prevalence. Data from the Navajo Health and Nutrition Survey showed that one third of Navajo adults with diabetes had not had diabetes diagnosed (9 ) . Third, under the Indian Self-Determination Act † , an increasing number of service units are becoming IHS sites operated by tribal governments that may choose not to report diabetes cases to the IHS outpatient database. Finally, 11% of the total IHS population was excluded from this analysis because of incomplete data.
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Epidemic of Congenital Syphilis -Baltimore, 1996-1997
Congenital Syphilis -Continued In 1996 and 1997, Baltimore, Maryland, had the highest rate for primary and secondary syphilis among U.S. cities (1, 2 ) . From 1993 to 1996, the rate for congenital syphilis (CS) in Baltimore increased from 62 to 282 per 100,000 live-born infants. To assess the magnitude of the syphilis epidemic in pregnant women and to identify ways to improve CS prevention, the Baltimore City Health Department (BCHD), the Maryland Department of Health and Mental Hygiene (DHMH), and CDC analyzed CS surveillance data for and reviewed medical records of pregnant women with syphilis. This report summarizes the results of this investigation, which indicated that 90% of cases could have been prevented by adequate prenatal care and more timely syphilis screening and treatment.
BCHD surveillance data and hospital discharge records were reviewed to identify women who had active syphilis during pregnancy and deliveries during January 1, 1996-March 30, 1997, and to assess completeness of surveillance data. To identify factors associated with CS and possible prevention strategies, medical records of pregnant women with syphilis and of their infants were reviewed, and mother-infant pairs were classified as CS cases according to the CDC surveillance case definition for CS (3 ) or as controls.
The CS rate in Baltimore increased from 62 per 100,000 live-born infants in 1993 to 282 in 1996. The increase among blacks was from 113 in 1993 to 564 in 1996 ( Figure 1 ). During the study period, 90 women were identified who had active syphilis during pregnancy and who delivered infants. Of these, 62 (69%) women delivered infants with illnesses meeting the CS case definition; 28 (31%) women (controls) who were adequately treated for syphilis during pregnancy delivered infants who did not have CS. All infants with CS had been reported to BCHD. Of the 62 mothers of casepatients, four (7%) delivered stillborn infants. Mothers of case-patients and mothers of controls had similar demographic characteristics. Of the 90 women, the mean age was 26 years; 86 (96%) were black; 72 (80%) were single; 78 (87%) were unemployed; 28 (31%) had multiple addresses during pregnancy; and six (11%) of 56 mothers tested were HIV-infected. A total of 54 (60%) had either a positive toxicology screen or self-reported cocaine or heroin use during pregnancy; 24 (44%) of 54 had a record of substance-abuse treatment. Of those women tested by toxicology screen at delivery, nine (23%) of 40 mothers of case-patients and 10 (53%) of 19 mothers of controls were positive for cocaine (p<0.03), four (10%) of 40 mothers of case-patients and one (5%) of 19 mothers of controls were positive for heroin, and 13 (33%) of 40 mothers of casepatients and one (5%) of 19 mothers of controls (p<0.05) were positive for both drugs.
Mothers of case-patients and mothers of controls differed with respect to several prenatal care-related factors. Of the 58 mothers of case-patients, 43 (74%) had a third trimester diagnosis of syphilis compared with eight (29%) of 28 mothers of controls (p<0.01). Records of mothers of case-patients were more likely than mothers of controls to include documentation suggesting their pregnancy was unintended (37% versus 14%) (p<0.05). Among the 90 mothers, three were allergic to penicillin; none was desensitized and treated with penicillin during pregnancy (4 ). Therefore, the three mothers delivered infants who had illnesses meeting the CS case definition.
Thirty-six (58%) mothers of case-patients had no prenatal care or initiated prenatal care late in the third trimester. Approximately 80% of these women had missed opportunities to be reached and referred during pregnancy: six (17%) had spent time in jail; 22 (61%) had contact with a social worker, and at least 16 (44%) were clients of other social service agencies.
Missed prevention opportunities also were identified for most of the mothers of case-patients who had had early prenatal care. At the time of this investigation, Maryland law required syphilis screening of all pregnant women in the first and third trimesters, but there was no stipulation on the timing of the third trimester test. Editorial Note: Congenital syphilis is one of the most devastating yet preventable outcomes of a sexually transmitted disease (STD). Fetal complications include spontaneous abortions and stillbirths, and infant complications include multisystem disorders and death. Treatment of maternal syphilis with penicillin is highly effective in preventing CS (5 ). However, infants born to inadequately treated mothers can require parenteral therapy at an estimated cost of more than $12,000 per infant (6 ) . The findings in this report indicate that adequate prenatal care and timely syphilis screening and treatment could have prevented 90% of CS cases that occurred in Baltimore during the study period. The CS epidemic in Baltimore occurred despite dramatic declines in syphilis incidence in the United States. Nationally, CS declined 72% from a peak of 107 cases per 100,000 live-born infants in 1991 to 30 in 1996; in Baltimore, the rate was nearly 10-fold higher in 1996 than the national rate. Among blacks, the national rate was 128 per 100,000 live-born infants in 1996 compared with 564 in Baltimore. The large racial differential in CS rates suggests that other factors for which race is often a proxy (e.g., differential access to and quality of health-care services) may be contributing to this epidemic and differentially affecting blacks (7 ) .
The prevalence of drug use was high among all women who had syphilis during pregnancy. However, in this investigation, the type of drugs used differed between mothers of case-patients and mothers of controls. For example, heroin use, either alone or in addition to cocaine use, was significantly associated with CS, and cocaine use alone was not significantly associated with CS among this group of women who had syphilis during pregnancy. These results may not be generalizable to other populations.
The findings in this report are subject to at least two limitations. First, most of the data were gathered through record review. As a result, key variables (e.g., unintended pregnancy and detention history) may be underreported. Second, because spontaneous abortions were not included, stillborn infants may be underascertained. Despite these limitations, the finding that lack of adequate prenatal care was associated with CS is consistent with other studies (8, 9 ) .
Although reducing the risk for CS will ultimately depend on control of adult syphilis, prevention specific to pregnant women with active syphilis is feasible. In response to this epidemic, BCHD has alerted prenatal-care providers and worked with other health-care service providers to initiate screening and treatment programs for women of reproductive age. Through collaborative efforts of DHMH, BCHD, the Maryland Department of Public Safety and Correctional Services, and CDC, a rapid screening and treatment program for detainees and female arrestees was initiated at the Baltimore Central Booking Intake Center. Such interventions have been successful in other settings (10 ) . STD clinical services have been strengthened at public STD clinics, including additional clinicians and other staff. In addition, the Maryland regulation on syphilis testing during pregnancy was amended in January 1998 to require a third trimester screening test at 28 weeks' gestation or the first visit thereafter to ensure diagnosis in time to prevent perinatal transmission. A Baltimore City Commissioner's order was also issued mandating syphilis screening at delivery.
Congenital Syphilis -Continued
Adult Blood Lead Epidemiology and SurveillanceUnited States, First Quarter 1998, and Annual 1994-1997
Adult Blood Lead Epidemiology and Surveillance -Continued CDC, in collaboration with state and local health departments, monitors laboratoryreported elevated blood lead levels (BLLs) among adults in the United States. During 1998, 27 states* reported surveillance data to the Adult Blood Lead Epidemiology and Surveillance (ABLES) program. This report presents ABLES data for the first quarter of 1998 compared with the first quarter of 1997, annual data for 1997 compared with 1996, and prevalence and incidence of elevated BLLs from 1994 through 1997. The findings indicate that approximately 4000 adults per quarter and an estimated 12,000 adults per year continue to have elevated BLLs; there does not appear to be a trend in these data from 1994 through 1997.
Beginning with the previous ABLES report (1 ), emphasis has been placed on the number of persons with elevated BLLs (prevalence); prior ABLES reports focused primarily on the number of laboratory reports of elevated BLLs (there are often multiple laboratory reports for the same person). The number of new cases of elevated BLLs (incidence) is reported as cumulative annual data.
States in the ABLES program mandate that laboratories report elevated BLLs for adults to the state health department or another designee. The minimum BLL required to be reported varies among the states; the ABLES definition of an elevated BLL is ≥25 µg/dL. ABLES follow-back procedures for identifying source of exposures and preventing future exposures have been described previously (2 ) .
Prevalence is defined as all cases (new plus existing) of persons with at least one BLL ≥25 µg/dL during the year. Incidence is defined as all new cases of persons with at least one BLL ≥25 µg/dL appearing in state surveillance data in the year who were not recorded during the preceding year. Denominators for prevalence and incidence were derived by subtracting the number of persons aged ≥65 years in the state from the total number of persons aged ≥16 years in the state. †
First Quarter Reports, 1998
During January 1-March 31, 1998, 3895 persons were reported with BLLs ≥25 µg/dL, representing a 20% decrease compared with 4885 persons reported for the first quarter of 1997 (3 ), § and a 3% decrease compared with 4010 reported for the fourth quarter of 1997 (1 ) (Figure 1 ). Of the 3895, 155 (4%) were reported with BLLs ≥50 µg/dL, the level designated by the Occupational Safety and Health Administration (OSHA) for medical removal from the workplace (4 ), representing a 37% decrease compared with 245 reported for the first quarter of 1997, and a 34% decrease compared with the 236 reported for the fourth quarter of 1997 (Figure 1 ).
Annual Reports, 1997
The number of persons with BLLs ≥25 µg/dL reported to the ABLES program increased by 5% from 12,073 in 1996 to 12,716 in 1997, with the same 27 states reporting in each year (3 ) . ¶ The number of persons with BLLs ≥50 µg/dL decreased by 1% from 787 in 1996 to 777 in 1997.
The reported number of new cases with BLLs ≥25 µg/dL decreased by 12% from 6115 in 1996 to 5397 in 1997, with the same 27 states reporting in each year. New cases with BLLs ≥50 µg/dL decreased by 9% from 456 in 1996 to 417 in 1997.
Prevalence and Incidence, 1994-1997
The number of states reporting to ABLES increased from four in 1987 to 23 in 1994 and 27 in 1997. Because of this increase, comparing current ABLES raw numeric data with raw numeric data from previous years has required adjustment for the number of states reporting. Beginning with this report, prevalence and incidence will be used to facilitate comparisons of ABLES data over time.
Overall prevalence rates ranged from 104 per million adults aged 16-64 years in 1994 to 111 in 1997 (Figure 2 ). Of the 22 states that reported throughout 1994-1997, 11 had lower prevalence rates in 1997 than in 1994, and 11 had higher rates. Overall incidence ranged from 53 per million adults aged 16-64 years in 1994 to 47 in 1997 † Population figures are available from the World-Wide Web site http://www.census.gov/ population/estimates/state/97agesex.txt. § To compare the number of persons for a constant roster of 27 states in 1998 and 1997, an estimate of first quarter 1997 data for Illinois, which discontinued reporting in 1996, was subtracted from previously reported totals for the first quarter of 1997 (3 ). ¶ To compare data for a constant roster of 27 states in 1996 and 1997, data for 1997 for New Mexico, Rhode Island, and Wyoming were added to the previously reported totals for 1996, and data for 1996 for Illinois (which discontinued reporting at the end of 1996) were subtracted from the previously reported totals for 1996 (3 ). Previously reported 1996 data for Minnesota and Ohio were updated for this report.
( Figure 2 ). Of the 22 states that reported throughout 1994-1997, the incidence in 1997 compared with 1994 was lower in 13 states, higher in eight states, and unchanged in one. The annual data for 1997 for the 27 ABLES states show a 5% increase in the number of persons and a 12% decrease in the number of new cases with BLLs ≥25 µg/dL compared with 1996 and adjusted for the increase in the number of participating states in 1997. Based on data for 1994-1997, however, these changes from 1996 to 1997 do not seem to represent a change from the overall pattern of prevalence and incidence during 1994-1997; a recognizable trend in the combined ABLES data during this period is not evident. Variation in the number of detected cases reported to ABLES may reflect 1) changes in the year-to-year efforts of the various participating states, and leadusing industries within them, to identify lead-exposed workers and prevent new lead exposures; 2) changes in occupational exposures to lead; 3) changes in compliance with OSHA requirements regarding blood lead monitoring; and/or 4) changes in the size of the workforce in lead-using industries. Variation in quarterly and annual nationwide reporting totals also might represent normal fluctuations in case reporting, which may result from changes in staffing and funding in state-based surveillance programs, interstate differences in worker BLL testing by lead-using industries, or random variation.
The findings in this report document the continuing hazard of lead exposures as an occupational health problem in the United States. ABLES enhances surveillance for this preventable condition by expanding the number of participating states, exploring ways to increase the usefulness of reporting, and alerting the public to potential new sources of lead exposure.
Notice to Readers
Use of Short-Course Tuberculosis Preventive Therapy Regimens in HIV-Seronegative Persons
Notices to Readers -Continued In the MMWR Recommendations and Reports, Prevention and Treatment of Tuberculosis Among Patients Infected with Human Immunodeficiency Virus: Principles of Therapy and Revised Recommendations (1 ) , CDC has recommended the use of a 2-month regimen of daily rifampin and pyrazinamide (2RZ) as an alternative to a 12-month regimen of isoniazid for the prevention of tuberculosis in HIV-infected persons with positive tuberculin skin test reactions. This recommendation is based on the results of several randomized, controlled clinical trials in HIV-infected persons. Next year, CDC, in conjunction with the American Thoracic Society, expects to issue new guidelines on screening and preventive therapy for tuberculosis that will include a recommendation on the use of the 2RZ regimen for HIV-negative persons for whom preventive therapy is indicated. This recommendation will note that a comparative trial of the 2RZ regimen in HIV-negative persons has not been conducted and that additional data will be needed on acceptability and toxicity to determine whether it is a cost-effective alternative to longer courses of isoniazid.
Until new guidelines are issued, the regimen for HIV-positive persons can be used for HIV-negative persons, following the same guidelines for HIV-positive persons. This regimen may be useful especially in settings where provision of longer courses of Vol. 47 / No. 42 MMWRpreventive therapy has not been feasible (e.g., jails). CDC's Division of Tuberculosis Elimination (DTBE), National Center for HIV, STD, and TB Prevention, will collect information on completion of preventive therapy from selected programs using the shortcourse regimen. Programs interested in working with the DTBE in this effort can contact CDC, telephone (404) 639-8123. CDC designates this educational activity for a maximum of 2.0 hours in category 1 credit toward the American Medical Association's Physician's Recognition Award. CDC also is accredited by the American Nurses Credentialing Center's Commission on Accreditation to provide continuing education for nurses. CDC designates this educational activity for a maximum of 2.4 contact hours of CNE credit.
To register and to receive credit, physicians and nurses must return their responses either electronically to the World-Wide Web site http://www.cdc.gov/epo/mmwr/ mmwr.html, then go to Continuing Education Program for Physicians and Nurses, or by a card or letter postmarked by October 30, 1999. There is no fee for participating in this continuing education activity. CME and CNE components are planned for future MMWR Recommendations and Reports.
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